Therapeutic potential of α-glucosidase inhibitors in type 2 diabetes mellitus: An evidence-based review

Expert Opinion on Pharmacotherapy

Volumn 16, Issue 13, 2015, Pages 1959-1981

  Joshi, Shashank R ^a   Standl, Eberhard ^b   Tong, Nanwei ^c   Shah, Parag ^d   Kalra, Sanjay ^e   Rathod, Rahul ^f  

^a Dr Joshi's Imaging Clinic Mumbai   (India)

^b Helmholtz Centre for Environmental Health   (Germany)

^c SICHUAN UNIVERSITY   (China)

^d Silver Brook A   (India)

^e Endocrinology Department ^*  (India)

^f Bayer Zydus Pharma Private Limited   (India)

Author keywords

acarbose; cardiovascular disease; diabetes mellitus; miglitol; postprandial hyperglycemia; type 2; voglibose; glucosidase inhibitors

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; GLUCOSE; INCRETIN; INSULIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSIDASE INHIBITOR;

DIABETES CONTROL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEART PROTECTION; HUMAN; HYPOGLYCEMIA; INTESTINE FLORA; LIPID METABOLISM; META ANALYSIS; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PATIENT; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; WEIGHT REDUCTION; ANALYSIS; ARTERIAL WALL THICKNESS; CARDIOVASCULAR DISEASES; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; HYPERGLYCEMIA; PATHOLOGY;

ACARBOSE; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CAROTID INTIMA-MEDIA THICKNESS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; GLYCOSIDE HYDROLASE INHIBITORS; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 84939807380     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2015.1070827     Document Type: Review

References (194)

1. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-12
2. Monnier L, Colette C. Target for glycemic control: concentrating on glucose. Diabetes Care 2009; 32 (Suppl 2): S199-204
3. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003; 26: 881-5
4. Ning F, Tuomilehto J, Pyörälä K, et al. DECODE Study Group. Cardiovascular disease mortality in Europeans in relation to fasting and 2-h plasma glucose levels within a normoglycemic range. Diabetes Care 2010; 33: 2211-16
5. DECODE Study Group; the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001; 161: 397-405
6. Marfella R, Quagliaro L, Nappo F, et al. Acute hyperglycemia induces an oxidative stress in healthy subjects. J Clin Invest 2001; 108: 635-6
7. Kawano H, Motoyama T, Hirashima O, et al. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol 1999; 34: 146-54
8. Esposito K, Nappo F, Marfella R, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002; 106: 2067-72
9. Node K, Inoue T. Postprandial hyperglycemia as an etiological factor in vascular failure. Cardiovasc Diabetol 2009; 8: 23
10. International Diabetes Federation. Guideline for management of postmeal Glucose. 2011. Available from: http://www.idf.org/sites/default/files/postmeal%20glucose%20guidelines.pdf. [Last accessed on 05 March 2015]
11. American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care 2014; 37 (Suppl 1): S14-80
12. Wolever TM, Bolognesi C. Source and amount of carbohydrate affect postprandial glucose and insulin in normal subjects. J Nutr 1996; 126: 2798-806
13. Joshi SR. Post-prandial Carbohydrate Modulation via Gut-Indian Perspective. J Assoc Physicians India 2010; 58: 665
14. Joshi SR, Mohan V, Joshi SS, et al. Transcultural diabetes nutrition therapy algorithm: the Asian Indian application. Curr Diab Rep 2012; 12: 204-12
15. Joshi SR, Bhansali A, Bajaj S, et al. Results from a dietary survey in an Indian T2DM population: a STARCH study. BMJ Open 2014; 4: e005138
16. Joshi SR, Karne R. Pre-diabetes, dysglycaemia and early glucose intolerance and vascular health. J Assoc Physicians India 2007; 55: 829-31
17. Philip E, Sundaram ML, Das R, et al. Acarbose improves glycemic control as add-on or monotherapy in Indian type-2 diabetes: Findings from the GlucoVIP multinational observational study. Indian J Endocrinol Metab 2013; 17 (Suppl 3): S674-9
18. DECODE Study Group. Age-And sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. Diabetes Care 2003; 26: 61-9
19. Qiao Q, Hu G, Tuomilehto J, et al. DECODA Study Group. Age-And sex-specific prevalence of diabetes and impaired glucose regulation in 11 Asian cohorts. Diabetes Care 2003; 26: 1770-80
20. Chowdhury TA, Lasker SS. Complications and cardiovascular risk factors in South Asians and Europeans with early-onset type 2 diabetes. QJM 2002; 95: 241-6
21. Ma RC, Chan JC. Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States. Ann N Y Acad Sci 2013; 1281: 64-91
22. Lear SA, Humphries KH, Kohli S, et al. Visceral adipose tissue accumulation differs according to ethnic background: results of the Multicultural Community Health Assessment Trial (M-CHAT). Am J Clin Nutr 2007; 86: 353-9
23. Hu FB. Globalization of diabetes: the role of diet, lifestyle, and genes. Diabetes Care 2011; 34: 1249-57
24. Bakker LE, Sleddering MA, Schoones JW, et al. Pathogenesis of type 2 diabetes in South Asians. Eur J Endocrinol 2013; 169: R99-114
25. Dickinson S, Colagiuri S, Faramus E, et al. Postprandial hyperglycemia and insulin sensitivity differ among lean young adults of different ethnicities. J Nutr 2002; 132: 2574-9
26. Chan JC, Malik V, Jia W, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 2009; 301: 2129-40
27. Liew CF, Seah ES, Yeo KP, et al. Lean, nondiabetic Asian Indians have decreased insulin sensitivity and insulin clearance, and raised leptin compared to Caucasians and Chinese subjects. Int J Obes Relat Metab Disord 2003; 27: 784-9
28. Sheth T, Nair C, Nargundkar M, et al. Cardiovascular and cancer mortality among Canadians of European, south Asian and Chinese origin from 1979 to 1993: an analysis of 1.2 million deaths. CMAJ 1999; 161: 132-8
29. Chandie Shaw PK, Baboe F, van Es LA, et al. South-Asian type 2 diabetic patients have higher incidence and faster progression of renal disease compared with Dutch-European diabetic patients. Diabetes Care 2006; 29: 1383-5
30. Inzucchi SE, Bergenstal RM, Buse JB, et al. American Diabetes Association (ADA);European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-79
31. Chia CW, Egan JM. Incretin-based therapies in type 2 diabetes mellitus. J Clin Endocrinol Metab 2008; 93: 3703-16
32. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999; 131: 281-303
33. Cornell S. Continual evolution of type 2 diabetes: an update on pathophysiology and emerging treatment options. Ther Clin Risk Manag 2015; 11: 621-32
34. Yang W, Liu J, Shan Z, et al. Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomized trial. Lancet Diabetes Endocrinol 2014; 2: 46-55
35. International Diabetes Federation, Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes-2012. 2012. Available from: http://www.idf.org/sites/default/files/IDF%20T2DM%20Guideline.pdf. [Last accessed 18 Mar 2015]
36. Garber AJ, Abrahamson MJ, Barzilay JI, et al. American Association of Clinical Endocrinologists. AACE comprehensive diabetes management algorithm 2013. Endocr Pract 2013; 19: 327-36
37. Chinese Diabetes Society. China guideline for type 2 diabetes. Chin J Dia 2010 (Suppl 2): 1-56
38. Ko SH, Kim SR, Kim DJ, et al. Committee of Clinical Practice Guidelines, Korean Diabetes Association. 2011 clinical practice guidelines for type 2 diabetes in Korea. Diabetes Metab J 2011; 35: 431-6
39. Japan Diabetes Society. Treatment guideline for diabetes. 2012-2013. Available from: http://www.jds.or.jp/common/fckeditor/editor/filemanager/connectors/php/transfer.php?file=/uid000025-54726561746D656E745F47756964655F666F725F44696162657465735F323031322D323031332E706466. [Last accessed 18 March 2015]
40. Indian Council of Medical Research. Guidelines for management of type 2 diabetes, New Delhi, Indian Council of Medical Research. 2005. Available from: http://www.icmr.nic.in/guidelines-diabetes/guide-diabetes.htm. [Last accessed 05 March 2015]
41. Sheu WH, Rosman A, Mithal A, et al. Addressing the burden of type 2 diabetes and cardiovascular disease through the management of postprandial hyperglycaemia: an Asian-Pacific perspective and expert recommendations. Diabetes Res Clin Pract 2011; 92: 312-21
42. API-ICP Guidelines on Diabetes 2007. J Assoc Physicians India 2007; 55: 1-50
43. Sinha A, Rajan M, Hoerger T, et al. Costs and consequences associated with newer medications for glycemic control in type 2 diabetes. Diabetes Care 2010; 33 (4): 695-700
44. Hanefeld M. Alpha-glucosidase inhibitors. In: Goldstein BJ, Mueller-Wieland D.,. editors. Alpha-glucosidase inhibitors: principles and practice. 2nd edition. CRC press, Boca Raton, FL, USA; 2007. p. 121-34
45. Weng J, Soegondo S, Schnell O, et al. Efficacy of acarbose in different geographical regions of the world: analysis of a real-life database. Diabetes Metab Res Rev 2015; 31 (2): 155-67
46. Precose 2011. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/020482s024lbl.pdf. [Last accessed 05 March 2015]
47. Puls W. Pharmacology of glucosidase inhibitors. Oral Antidiabetics 1996; 119: 497-525
48. Sels JP, Huijberts MS, Wolffenbuttel BH. Miglitol, a new alpha-glucosidase inhibitor. Expert Opin Pharmacother 1999; 1: 149-56
49. Chen X, Zheng Y, Shen Y. Voglibose (Basen, AO-128), one of the most important alpha-glucosidase inhibitors. Curr Med Chem 2006; 13: 109-16
50. Kalra S, Chadha M, Sharma SK, et al. Untapped diamonds for untamed diabetes: The alpha-glucosidase inhibitors. Indian J Endocrinol Metab 2014; 18: 138-41
51. Van de Laar FA, Lucassen PLBJ, Akkermans RP, et al. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev; 2005; 18 (2): CD003639
52. Rosak C, Mertes G. Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations. Diab Metab Syndr Obes 2012; 5: 357-67
53. Yoon SH, Robyt JF. Study of the inhibition of four alpha amylases by acarbose and its 4IV-Alpha-maltohexaosyl and 4IV-Alpha-maltododecaosyl analogues. Carbohydr Res 2003; 338: 1969-80
54. Kalra S. Alpha glucosidase inhibitors. J Pak Med Assoc 2014; 474: 6
55. Voglibose dispersible tablets. Available from: http://www.biocon.com/docs/prescribing-information/diabetology/volicose-pi.pdf. [Last accessed 05 March 2015]
56. Scott LJ, Spencer CM, Miglitol-A. Review of its Therapeutic Potential in Type 2 Diabetes Mellitus. Drugs 2000; 59: 521-49
57. Glyset® miglitol tablets 2008. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/020682s008lbl.pdf. [Last accessed 05 March 2015]
58. Dabhi AS, Bhatt NR, Shah MJ. Voglibose: An Alpha Glucosidase Inhibitor. J Clin Diagn Res 2013; 7: 3023-7
59. Agrawal D, Kumar S, et al. Alfa glucosidase inhibitor: voglibose can prevent progression of impaired glucose tolerance stage to type ii diabetes mellitus. RJPBCS 2014; 5: 654-61
60. Brunetti L, Kalabalik J. Management of type-2 diabetes mellitus in adults: focus on individualizing non-insulin therapies. P T 2012; 37: 687-96
61. Rosak C, Nitzsche G, König P, et al. The effect of the timing and the administration of acarbose on postprandial hyperglycaemia. Diabet Med 1995; 12: 979-84
62. Joshi SR, Ramachandran A, Chadha M, et al. Acarbose plus metformin fixed-dose combination in the management of type 2 diabetes. Expert Opin Pharmacother 2014; 15: 1611-20
63. Ren F, Chen L, Tong Q. Application of TLC in the Screening of Acarbose-producing Actinomycetes. Adv J Food Sci Technol 2014; 6: 629-33
64. Acarbose, Miglitol and Voglibose. Citeline Pharmaprojects®. 2015. Available from: http://www.citeline.com/category/pharmaprojects/. [Last accessed 18 March 2015]
65. Sheehan MT. Current therapeutic options in type 2 diabetes mellitus: a practical approach. Clin Med Res 2003; 1: 189-200
66. Ibrahim R. Diabetes mellitus type II: review of oral treatment options. Int J Pharm Pharmaceut Sci 2010; 2 (Suppl 1): 21-30
67. Newer Diabetes Medications, TZDs, and Combinations. Available from: http://www.hca.wa.gov/pdp/Documents/Linagliptin-report.pdf. [Last accessed 18 March 2015]
68. Pan CY, Landen H. Post-marketing surveillance of acarbose treatment in patients with type 2 diabetes mellitus and subjects with impaired glucose tolerance in China. Clin Drug Investig 2007; 27: 397-405
69. Dimitriadis G, Karaiskos C, Raptis S. Effects of prolonged (6 months) alpha-glucosidase inhibition on blood glucose control and insulin requirements in patients with insulin-dependent diabetes mellitus. Horm Metab Res 1986; 18: 253-5
70. Sels JP, Verdonk HE, Wolffenbuttel BH. Effects of acarbose (Glucobay) in persons with type 1 diabetes: a multicentre study. Diabetes Res Clin Pract 1998; 41: 139-45
71. Riccardi G, Giacco R, Parillo M, et al. Efficacy and safety of acarbose in the treatment of Type 1 diabetes mellitus: a placebo-controlled, double-blind, multicentre study. Diabet Med 1999; 16: 228-32
72. Fischer S, Hanefeld M, Spengler M, et al. European study on dose-response relationship of acarbose as a first-line drug in non-insulin-dependent diabetes mellitus: efficacy and safety of low and high doses. Acta Diabetol 1998; 35: 34-40
73. Pan C, Yang W, Barona JP, et al. Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet Med 2008; 25: 435-41
74. Pan CY, Gao Y, Li GW, et al a comparison of efficacy and tolerance of nateglinide and acarbose monotherapy in type 2 diabetes mellitus. Zhonghua Nei Ke Za Zhi 2009; 48: 304-7
75. Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients: the Essen Study. Diabetes Care 1994; 17: 561-6
76. Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-Treated NIDDM patients: the Essen-II Study. Am J Med 1997; 103: 483-90
77. Wang G, Liu J, Yang N, et al. MARCH2: comparative assessment of therapeutic effects of acarbose and metformin in newly diagnosed type 2 diabetes patients. PLoS One 2014; 9: e105698
78. Yang G, Li C, Gong Y, et al a prospective, randomized, open-label study comparing the efficacy and safety of preprandial and prandial insulin in combination with acarbose in elderly, insulin-requiring patients with type 2 diabetes mellitus. Diabetes Technol Ther 2013; 15: 513-19
79. Drent ML, Tollefsen AT, van Heusden FH, et al. Dose-dependent efficacy of miglitol, an alpha-glucosidase inhibitor, in type 2 diabetic patients on diet alone: results of a 24-week double-blind placebo-controlled study. Diabetes Nutr Metab 2002; 15: 152-9
80. Johnston PS, Lebovitz HE, Coniff RF, et al. Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients. J Clin Endocrinol Metab 1998; 83: 1515-22
81. Van de Laar FA, Lucassen PL, Akkermans RP, et al. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005 (2): CD003639
82. Iwamoto Y, Kashiwagi A, Yamada N, et al. Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study. Diabetes Obes Metab 2010; 12: 700-8
83. Matsumura M, Monden T, Miyashita Y, et al. Effects of changeover from voglibose to acarbose on postprandial triglycerides in type 2 diabetes mellitus patients. Adv Ther 2009; 26: 660-6
84. Zhu Q, Tong Y, Wu T, et al. Comparison of the hypoglycemic effect of acarbose monotherapy in patients with type 2 diabetes mellitus consuming an Eastern or Western diet: a systematic meta-Analysis. Clin Ther 2013; 35: 880-99
85. Mertes G. Safety and efficacy of acarbose in the treatment of Type 2 diabetes: data from a 5-year surveillance study. Diabetes Res Clin Pract 2001; 52: 193-204
86. Chiasson JL, Naditch L,; Miglitol Canadian University Investigator Group. The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes. Diabetes Care 2001; 24: 989-94
87. Kingma PJ, Menheere PP, Sels JP, et al. Alpha-Glucosidase inhibition by miglitol in NIDDM patients. Diabetes Care 1992; 15: 478-83
88. Hariya N, Mochizuki K, Inoue S, et al. Switching alpha-glucosidase inhibitors to miglitol reduced glucose fluctuations and circulating cardiovascular disease risk factors in type 2 diabetic Japanese patients. Drugs R D 2014; 14: 177-84
89. Vichayanrat A, Ploybutr S, Tunlakit M, et al. Efficacy and safety of voglibose in comparison with acarbose in type 2 diabetic patients. Diabetes Res Clin Pract 2002; 55: 99-103
90. Halimi S, Le Berre MA, Grangé V. Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with Type 2 diabetes inadequately controlled with metformin: a double-blind, placebo-controlled study. Diabetes Res Clin Pract 2000; 50: 49-56
91. Phillips P, Karrasch J, Scott R, et al. Acarbose improves glycemic control in overweight type 2 diabetic patients insufficiently treated with metformin. Diabetes Care 2003; 26: 269-73
92. Rosenstock J, Brown A, Fischer J, et al. Efficacy and safety of acarbose in metformin-Treated patients with type 2 diabetes. Diabetes Care 1998; 21: 2050-5
93. Jayaram S, Hariharan RS, Madhavan R, et al a prospective, parallel group, open-labeled, comparative, multi-centric, active controlled study to evaluate the safety, tolerability and benefits of fixed dose combination of acarbose and metformin versus metformin alone in type 2 diabetes. J Assoc Physicians India 2010; 58: 679-82, 687
94. Willms B, Ruge D. Comparison of acarbose and metformin in patients with Type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: a randomized, placebo-controlled study. Diabet Med 1999; 16: 755-61
95. Saboo B, Reddy GC, Juneja S, behalf of GLOBE Investigators. Effectiveness and safety of fixed dose combination of acarbose/metformin in Indian Type 2 diabetes patients: Results from observational GLOBE Study. Indian J Endocrinol Metab 2015; 19: 129-35
96. Rosak C, Haupt E, Walter T, et al. The effect of combination treatment with acarbose and glibenclamide on postprandial glucose and insulin profiles: additive blood glucose lowering effect and decreased hypoglycaemia. Diabetes Nutr Metab 2002; 15: 143-51
97. Kusunoki Y, Katsuno T, Myojin M, et al. Effect of additional administration of acarbose on blood glucose fluctuations and postprandial hyperglycemia in patients with type 2 diabetes mellitus under treatment with alogliptin. Endocr J 2013; 60: 431-9
98. Derosa G, Salvadeo SA, DAngelo A, et al. Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial. Curr Med Res Opin 2009; 25: 607-15
99. Josse RG. Acarbose for the treatment of type II diabetes: the results of a Canadian multi-centre trial. Diabetes Res Clin Pract 1995; 28 (Suppl): S167-72
100. Gentile S, Turco S, Guarino G, et al. Effect of treatment with acarbose and insulin in patients with non-insulin-dependent diabetes mellitus associated with non-Alcoholic liver cirrhosis. Diabetes Obes Metab 2001; 3: 33-40
101. Hsieh SH, Shih KC, Chou CW, et al. Evaluation of the efficacy and tolerability of miglitol in Chinese patients with type 2 diabetes mellitus inadequately controlled by diet and sulfonylureas. Acta Diabetol 2011; 48: 71-7
102. Van Gaal L, Maislos M, Schernthaner G, et al. Miglitol combined with metformin improves glycaemic control in type 2 diabetes. Diabetes Obes Metab 2001; 3: 326-31
103. Standl E, Schernthaner G, Rybka J, et al. Improved glycaemic control with miglitol in inadequately-controlled type 2 diabetics. Diabetes Res Clin Pract 2001; 51: 205-13
104. Mitrakou A, Tountas N, Raptis AE, et al. Long-Term effectiveness of a new alpha-glucosidase inhibitor (BAY m1099-miglitol) in insulin-Treated type 2 diabetes mellitus. Diabet Med 1998; 15: 657-60
105. Takahara M, Shiraiwa T, Katakami N, et al. Efficacy of adding once-And thrice-daily voglibose in Japanese type 2 diabetic patients treated with alogliptin. Endocr J 2014; 61: 447-56
106. Jindal A, Jindal M, Kaur M, et al. Efficacy and safety of voglibose as an add-on triple drug in patients of type two diabetes mellitus uncontrolled with glimepiride and metformin in Punjabi population. Indian J Basic Appl Med Res 2014; 3: 111-16
107. Saito N, Sakai H, Suzuki S, et al. Effect of an alpha-glucosidase inhibitor (voglibose), in combination with sulphonylureas, on glycaemic control in type 2 diabetes patients. J Int Med Res 1998; 26: 219-32
108. Kim MK, Suk JH, Kwon MJ, et al. Nateglinide and acarbose for postprandial glucose control after optimizing fasting glucose with insulin glargine in patients with type 2 diabetes. Diabetes Res Clin Pract 2011; 92: 322-8
109. Schnell O, Mertes G, Standl E,; Acarbose-Insulin Combination Study Group. Acarbose and metabolic control in patients with type 2 diabetes with newly initiated insulin therapy. Diabetes Obes Metab 2007; 9: 853-8
110. Lee MY, Choi DS, Lee MK, et al. Comparison of acarbose and voglibose in diabetes patients who are inadequately controlled with basal insulin treatment: randomized, parallel, open-label, active-controlled study. J Korean Med Sci 2014; 29: 90-7
111. Kimura T, Suzuki J, Ichikawa M, et al. Differential effects of alpha-glucosidase inhibitors on postprandial plasma glucose and lipid profile in patients with type 2 diabetes under control with insulin lispro mix 50/50. Diabetes Technol Ther 2012; 14: 545-51
112. Osonoi T, Saito M, Mochizuki K, et al. The alpha-glucosidase inhibitor miglitol decreases glucose fluctuations and inflammatory cytokine gene expression in peripheral leukocytes of Japanese patients with type 2 diabetes mellitus. Metabolism 2010; 59: 1816-22
113. Johnston PS, Coniff RF, Hoogwerf BJ, et al. Effects of the carbohydrase inhibitor miglitol in sulfonylurea-Treated NIDDM patients. Diabetes Care 1994; 17: 20-9
114. Kishimoto M, Noda M. Effect of the addition of sitagliptin and miglitol on insulin-Treated type 2 diabetes. Diabetes Ther 2012; 3: 11
115. Abe M, Kikuchi F, Kaizu K, et al. Combination therapy of pioglitazone with voglibose improves glycemic control safely and rapidly in Japanese type 2-diabetic patients on hemodialysis. Clin Nephrol 2007; 68: 287-94
116. Negishi M, Shimomura K, Proks P, et al. Alpha glucosidase inhibitor voglibose can prevent pioglitazone-induced body weight gain in Type 2 diabetic patients. Br J Clin Pharmacol 2008; 66: 318-19
117. Monami M, Vitale V, Ambrosio ML, et al. Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-Analysis of placebo-controlled trials. Adv Ther 2012; 29: 736-46
118. Chiasson JL, Josse RG, Gomis R, et al. STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003; 290: 486-94
119. Chou CW, Ou YH, Hsiao SH, et al. Differential Responses to Acarbose Between Obese and Non-obese Patients with Type 2 Diabetes Mellitus. Int J Endocrinol Metab 2006; 4: 63-9
120. Chen PH, Tsai YT, Wang JS, et al. Post-meal beta-cell function predicts the efficacy of glycemic control in patients with type 2 diabetes inadequately controlled by metformin monotherapy after addition of glibenclamide or acarbose. Diabetol Metab Syndr 2014; 6: 68
121. Cook MN, Girman CJ, Stein PP, et al. Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes. Diabetes Care 2005; 28: 995-1000
122. Riedel AA, Heien H, Wogen J, et al. Secondary failure of glycemic control for patients adding thiazolidinedione or sulfonylurea therapy to a metformin regimen. Am J Manag Care 2007; 13: 457-63
123. Delgado H, Lehmann T, Bobbioni-Harsch E, et al. Acarbose improves indirectly both insulin resistance and secretion in obese type 2 diabetic patients. Diabetes Metab 2002; 28: 195-200
124. Hanefeld M, Haffner SM, Menschikowski M, et al. Different effects of acarbose and glibenclamide on proinsulin and insulin profiles in people with Type 2 diabetes. Diabetes Res Clin Pract 2002; 55: 221-7
125. Chiasson JL, Josse RG, Gomis R, et al. STOP-NIDDM Trail Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359: 2072-7
126. Derosa G, Maffioli P, Ferrari I, et al. Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load. Eur J Pharmacol 2011; 651 (1-3): 240-50
127. Meneilly GS, Ryan EA, Radziuk J, et al. Effect of acarbose on insulin sensitivity in elderly patients with diabetes. Diabetes Care 2000; 23: 1162-7
128. Phung OJ, Scholle JM, Talwar M, et al. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 2010; 303: 1410-18
129. Meneghini LF, Orozco-Beltran D, Khunti K, et al. Weight beneficial treatments for type 2 diabetes. J Clin Endocrinol Metab 2011; 96: 3337-53
130. Gross JL, Kramer CK, Leitão CB, et al. Diabetes and Endocrinology Meta-Analysis Group (DEMA). Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-Analysis. Ann Intern Med 2011; 154: 672-9
131. McIntosh B, Cameron C, Singh SR, et al. Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-Treatment comparison meta-Analysis. Open Med 2011; 5: e35-48
132. Enç FY, Imeryüz N, Akin L, et al. Inhibition of gastric emptying by acarbose is correlated with GLP-1 response and accompanied by CCK release. Am J Physiol Gastrointest Liver Physiol 2001; 281: G752-63
133. Chan JC, Chan KW, Ho LL, et al. An Asian multicenter clinical trial to assess the efficacy and tolerability of acarbose compared with placebo in type 2 diabetic patients previously treated with diet. Asian Acarbose Study Group. Diabetes Care 1998; 21: 1058-61
134. Kalra S, Sahay RK, Schnell O, et al. Acarbose improves glycemic control and reduces body weight: Subanalysis data of South Asia region. Indian J Endocrinol Metab 2013; 17 (Suppl 1): S304-6
135. Li Y, Tong Y, Zhang Y, et al. Acarbose monotherapy and weight loss in Eastern and Western populations with hyperglycaemia: an ethnicity-specific meta-Analysis. Int J Clin Pract 2014; 68: 1318-32
136. Coniff RF, Shapiro JA, Seaton TB, et al. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-Acarbose in non-insulin-dependent diabetes mellitus. Am J Med 1995; 98: 443-51
137. Sugihara H, Nagao M, Harada T, et al. Comparison of three alpha-glucosidase inhibitors for glycemic control and bodyweight reduction in Japanese patients with obese type 2 diabetes. J Diabetes Investig 2014; 5: 206-12
138. Bischoff H. The mechanism of alpha-glucosidase inhibition in the management of diabetes. Clin Invest Med 1995; 18: 303-11
139. Kado S, Murakami T, Aoki A, et al. Effect of acarbose on postprandial lipid metabolism in type 2 diabetes mellitus. Diabetes Res Clin Pract 1998; 41: 49-55
140. Buse JB, Tan MH, Prince MJ, et al. The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes. Diabetes Obes Metab 2004; 6: 133-56
141. Båvenholm PN, Efendic S. Postprandial hyperglycaemia and vascular damage-The benefits of acarbose. Diab Vasc Dis Res 2006; 3: 72-9
142. Standl E, Theodorakis MJ, Erbach M, et al. On the potential of acarbose to reduce cardiovascular disease. Cardiovasc Diabetol 2014; 13: 81
143. Standl E, Schnell O. Alpha-glucosidase inhibitors 2012-cardiovascular considerations and trial evaluation. Diab Vasc Dis Res 2012; 9: 163-9
144. Rudofsky G Jr, Reismann P, Schiekofer S, et al. Reduction of postprandial hyperglycemia in patients with type 2 diabetes reduces NF-kappaB activation in PBMCs. Horm Metab Res 2004; 36: 630-8
145. Kato T, Inoue T, Node K. Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study. Cardiovasc Diabetol 2010; 9: 12
146. Patel YR, Kirkman MS, Considine RV, et al. Effect of acarbose to delay progression of carotid intima-media thickness in early diabetes. Diabetes Metab Res Rev 2013; 29: 582-91
147. Oyama T, Saiki A, Endoh K, et al. Effect of acarbose, an alpha-glucosidase inhibitor, on serum lipoprotein lipase mass levels and common carotid artery intima-media thickness in type 2 diabetes mellitus treated by sulfonylurea. J Atheroscler Thromb 2008; 15: 154-9
148. Koyasu M, Ishii H, Watarai M, et al. Impact of acarbose on carotid intima-media thickness in patients with newly diagnosed impaired glucose tolerance or mild type 2 diabetes mellitus: A one-year, prospective, randomized, open-label, parallel-group study in Japanese adults with established coronary artery disease. Clin Ther 2010; 32: 1610-17
149. Uzui H, Nakano A, Mitsuke Y, et al. Acarbose treatments improve arterial stiffness in patients with type 2 diabetes mellitus. J Diabetes Investig 2011; 2: 148-53
150. Hirano M, Nakamura T, Obata JE, et al. Early improvement in carotid plaque echogenicity by acarbose in patients with acute coronary syndromes. Circ J 2012; 76: 1452-60
151. Hanefeld M, Cagatay M, Petrowitsch T, et al. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-Analysis of seven long-Term studies. Eur Heart J 2004; 25: 10-16
152. Hiki M, Shimada K, Kiyanagi T, et al. Single administration of alpha-glucosidase inhibitors on endothelial function and incretin secretion in diabetic patients with coronary artery disease-Juntendo University trial: effects of miglitol on endothelial vascular reactivity in type 2 diabetic patients with coronary heart disease (J-MACH). Circ J 2010; 74: 1471-8
153. Nomura S, Omoto S, Yokoi T, et al. Effects of miglitol in platelet-derived microparticle, adiponectin, and selectin level in patients with type 2 diabetes mellitus. Int J Gen Med 2011; 4: 539-45
154. Nakamura K, Oe H, Kihara H, et al. DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study. Cardiovasc Diabetol 2014; 13: 110
155. Yamasaki Y, Katakami N, Hayaishi-Okano R, et al. Alpha-Glucosidase inhibitor reduces the progression of carotid intima-media thickness. Diabetes Res Clin Pract 2005; 67: 204-10
156. Pistrosch F, Schaper F, Passauer J, et al. Effects of the alpha glucosidase inhibitor acarbose on endothelial function after a mixed meal in newly diagnosed type 2 diabetes. Horm Metab Res 2009; 41: 104-8
157. Shimabukuro M, Higa N, Chinen I, et al. Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in type 2 diabetic patients: a randomized crossover study. J Clin Endocrinol Metab 2006; 91: 837-42
158. Emoto T, Sawada T, Hashimoto M, et al. Effect of 3-month repeated administration of miglitol on vascular endothelial function in patients with diabetes mellitus and coronary artery disease. Am J Cardiol 2012; 109: 42-6
159. Ceriello A, Taboga C, Tonutti L, et al. Post-meal coagulation activation in diabetes mellitus: the effect of acarbose. Diabetologia 1996; 39: 469-73
160. Tschoepe D. Decreased fibrinogen by treatment with the alpha-glucosidase inhibitor acarbose [ADA abstract 766]. Diabetes 2004; 53 (Suppl 2): A189
161. Derosa G, Maffioli P. Efficacy and safety profile evaluation of acarbose alone and in association with other antidiabetic drugs: a systematic review. Clin Ther 2012; 34: 1221-36
162. Wang X, Lu J, Pan C. Comparison of serum C-reactive protein level in different glucose tolerance subjects and the change in serum CRP level in IGT subjects with acarbose [abstract 1634]. Chin J Endocrinol Metab 2003; 19: 254-6
163. Hanefeld M, Pistrosch F, Koehler C, et al. Conversion of IGT to type 2 diabetes mellitus is associated with incident cases of hypertension: a post-hoc analysis of the STOP-NIDDM trial. J Hypertens 2012; 30: 1440-3
164. Rosenthal JH, Mauersberger H. Effects on blood pressure of the alpha-glucosidase inhibitor acarbose compared with the insulin enhancer glibenclamide in patients with hypertension and type 2 diabetes mellitus. Clin Drug Invest 2002; 22: 695-701
165. Holman RR, Bethel MA, Chan JC, et al. Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial. Am Heart J 2014; 168: 23-9.e2
166. Kawamori R, Tajima N, Iwamoto Y, et al. Voglibose Ph-3 Study Group. Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet 2009; 373: 1607-14
167. Moreno-Indias I, Cardona F, Tinahones FJ, et al. Impact of the gut microbiota on the development of obesity and type 2 diabetes mellitus. Front Microbiol 2014; 5: 190
168. Acarbose modulate Gut Bacteria in Patients with Type 2 Diabetes. American Diabetes Associations 74th Scientific Sessions, 2014, A-1573
169. Gentilcore D, Bryant B, Wishart JM, et al. Acarbose attenuates the hypotensive response to sucrose and slows gastric emptying in the elderly. Am J Med 2005; 118: 1289
170. Shimabukuro M, Higa M, Yamakawa K, et al. Miglitol, alpha-glycosidase inhibitor, reduces visceral fat accumulation and cardiovascular risk factors in subjects with the metabolic syndrome: a randomized comparable study. Int J Cardiol 2013; 167: 2108-13
171. Zheng MY, Yang JH, Shan CY, et al. Effects of 24-week treatment with acarbose on glucagon-like peptide 1 in newly diagnosed type 2 diabetic patients: a preliminary report. Cardiovasc Diabetol 2013; 12: 73
172. Suzuki Y, Sano M, Hayashida K, et al. Are the effects of alpha-glucosidase inhibitors on cardiovascular events related to elevated levels of hydrogen gas in the gastrointestinal tract? FEBS Lett 2009; 583: 2157-9
173. Kajiyama S, Hasegawa G, Asano M, et al. Supplementation of hydrogen-rich water improves lipid and glucose metabolism in patients with type 2 diabetes or impaired glucose tolerance. Nutr Res 2008; 28: 137-43
174. Kootte RS, Vrieze A, Holleman F, et al. The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitus. Diabetes Obes Metab 2012; 14: 112-20
175. Benli S. Modulation of Acarbose on Inflammatory Cytokines in Patients with Type 2 Diabetes. 74th Scientific Sessions Abstract Book San Francisco, California, USA. 2014. A-1591
176. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987; 2: 1300-4
177. Drucker DJ, Philippe J, Mojsov S, et al. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci USA 1987; 84: 3434-8
178. Bauer V, Sotníková R. Nitric oxide-The endothelium-derived relaxing factor and its role in endothelial functions. Gen Physiol Biophys 2010; 29: 319-40
179. Moritoh Y, Takeuchi K, Hazama M. Voglibose, an Alpha-glucosidase Inhibitor, to Increase Active Glucagon-like Peptide-1 Levels. Mol Cell Pharmacol 2009; 1: 188-92
180. Aoki K, Kamiyama H, Yoshimura K, et al. Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin. Acta Diabetol 2012; 49: 225-30
181. Holst JJ, Knop FK, Vilsboll T, et al. Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes. Diabetes Care 2011; 34 (Suppl 2): S251-7
182. Nauck MA, Vardarli I, Deacon CF, et al. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia 2011; 54: 10-18
183. Lin SD, Wang JS, Hsu SR, et al. The beneficial effect of alpha-glucosidase inhibitor on glucose variability compared with sulfonylurea in Taiwanese type 2 diabetic patients inadequately controlled with metformin: preliminary data. J Diabetes Complications 2011; 25: 332-8
184. Taira M, Takasu N, Komiya I, et al. Voglibose administration before the evening meal improves nocturnal hypoglycemia in insulin-dependent diabetic patients with intensive insulin therapy. Metabolism 2000; 49: 440-3
185. van de Laar FA, Lucassen PL, Akkermans RP, et al. Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-Analysis. Diabetes Care 2005; 28: 154-63
186. Tremaroli V, Bäckhed F. Functional interactions between the gut microbiota and host metabolism. Nature 2012; 489: 242-9
187. Balfour JA, McTavish D. Acarbose. An update of its pharmacology and therapeutic use in diabetes mellitus. Drugs 1993; 46: 1025-54
188. May C. Efficacy and tolerability of stepwise increasing dosage of acarbose in patients with non-insulin-dependent diabetes mellitus (NIDDM), treated with sulphonylureas. Diabetes Stoffwechsel 1995; 4: 3-8
189. Laube H. Acarbose: an update of its therapeutic use in diabetes treatment. Clin Drug Invest 2002; 22: 141-56
190. GLUCOBAY® 50, 100 2003. Avaialable from http://home.intekom.com/pharm/bayer/glucobay.html. [Last accessed 18 March 2015]
191. Campbell LK, Baker DE, Campbell RK. Miglitol: assessment of its role in the treatment of patients with diabetes mellitus. Ann Pharmacother 2000; 34: 1291-301
192. Karlsson FH, Tremaroli V, Nookaew I, et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 2013; 498: 99-103
193. Liu HX, Li J, Liu B, et al. Effect of acarbose on fecal bifidobacteria content in patients with type 2 diabetes mellitus. Chin J Endocrinol Metab 2011; 27: 47-50
194. Scheppach W, Fabian C, Ahrens F, et al. Effect of starch malabsorption on colonic function and metabolism in humans. Gastroenterology 1988; 95: 1549-55